Arbutus Biopharma (ABUS) Amortizatization of Intangibles (2019 - 2026)
Arbutus Biopharma (ABUS) posted Amortizatization of Intangibles of $354000.0 for Q1 2026, down 16.11% sequentially from $422000.0 in Q4 2025, and down 50.7% YoY from $718000.0 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Arbutus Biopharma has reported Amortizatization of Intangibles for 8 years, with the latest figure at $354000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 50.7% year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 39.85% YoY) and the FY2025 annual result came in at $2.3 million, down 25.07% from the prior year.
- Amortizatization of Intangibles eased to $354000.0 in Q1 2026 per ABUS's latest filing, from $422000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $983000.0 in Q3 2024 and troughed at -$168000.0 in Q1 2022.
- A 5-year average of $475764.7 and a median of $541000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles surged 743.37% in 2023, then plunged 54.28% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $224000.0 in 2022, then soared by 176.34% to $619000.0 in 2023, then jumped by 49.11% to $923000.0 in 2024, then slumped by 54.28% to $422000.0 in 2025, then decreased by 16.11% to $354000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $354000.0, $422000.0, and $541000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | 321,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 321,000.00 |
| Mar 31, 2026 | 354,000.00 |
| Dec 31, 2025 | 422,000.00 |
| Sep 30, 2025 | 541,000.00 |
| Jun 30, 2025 | 668,000.00 |
| Mar 31, 2025 | 718,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 983,000.00 |
| Jun 30, 2024 | 676,000.00 |
| Mar 31, 2024 | 553,000.00 |
| Dec 31, 2023 | 619,000.00 |
| Sep 30, 2023 | 658,000.00 |
| Jun 30, 2023 | 534,000.00 |
| Mar 31, 2023 | 385,000.00 |
| Dec 31, 2022 | 224,000.00 |
| Sep 30, 2022 | 81,000.00 |
| Jun 30, 2022 | -83,000.00 |
| Mar 31, 2022 | -168,000.00 |
| Dec 31, 2021 | -246,000.00 |
| Sep 30, 2021 | -300,000.00 |